The PredictAD clinical decision-support-system compares biomarkers' measurements of one patient to measurements of other patients available in large databases, and provides a simple index about the status/severity of the disease. The project has shown in several studies that the tool improves the accuracy of diagnosis and clinicians’ confidence about their decision. This way, PredictAD provides an efficient and reliable solution for early AD diagnosis.
In addition, the use of the disease state index also makes the follow-up of the disease progression and of the efficacy of the treatment possible, which are interesting when new treatments are developed.
Alzheimer’s disease (AD) covers 60-70% of all dementia cases. Currently no cure for AD exists, and effective and reliable early diagnostic techniques are lacking. PredictAD combines the best forces in Europe to solve this diagnostics problem, and hence strengthens EU leadership on the market.
The PredictAD topics are still very active. Here is a short summary of the ongoing issues:
- Kick-off meeting of the VPH-DARE@IT project which will extend the PredictAD results to differential diagnostics of dementias (the focus in PredictAD was only on Alzheimer’s disease which is the most common reason for dementia).
- Commercialisation is ongoing: we are working for getting approvals for the tool and have negotiations with different companies.
- Multiple validation studies have been published (since the end of the project) providing evidence that the tool enables earlier diagnostics.
The tool is still in its pilot test phase with prospective data for clinical use.
Funding: EU contribution 2,891,526€ out of 3,981,565€.
Project duration: From June 2008 to November 2011.